Natalizumab
Tysabri (natalizumab) is an antibody pharmaceutical. Natalizumab was first approved as Tysabri on 2004-11-23. It is used to treat crohn disease and multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against integrin alpha-4.
| Trade Name | Tysabri |
|---|---|
| Common Name | Natalizumab |
| Indication | crohn disease, multiple sclerosis |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
